About five million people worldwide have systemic lupus erythematosus (SLE), an autoimmune disease that damages organs and tissues throughout the body, including skin, joints, kidneys, heart, and ...
Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...
Zacks Small Cap Research on MSN
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL
By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results